BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 12574425)

  • 21. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.
    Laforet GA; Sapp E; Chase K; McIntyre C; Boyce FM; Campbell M; Cadigan BA; Warzecki L; Tagle DA; Reddy PH; Cepeda C; Calvert CR; Jokel ES; Klapstein GJ; Ariano MA; Levine MS; DiFiglia M; Aronin N
    J Neurosci; 2001 Dec; 21(23):9112-23. PubMed ID: 11717344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease.
    Rossi S; Prosperetti C; Picconi B; De Chiara V; Mataluni G; Bernardi G; Calabresi P; Centonze D
    Neurosci Lett; 2006 Dec; 410(1):6-10. PubMed ID: 17070651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formation of dendritic spines in cultured striatal neurons depends on excitatory afferent activity.
    Segal M; Greenberger V; Korkotian E
    Eur J Neurosci; 2003 Jun; 17(12):2573-85. PubMed ID: 12823464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
    Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
    Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons.
    Cepeda C; André VM; Yamazaki I; Wu N; Kleiman-Weiner M; Levine MS
    Eur J Neurosci; 2008 Feb; 27(3):671-82. PubMed ID: 18279319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3.
    Wójtowicz AM; Dvorzhak A; Semtner M; Grantyn R
    Front Neural Circuits; 2013; 7():188. PubMed ID: 24324407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.
    Centonze D; Rossi S; Prosperetti C; Tscherter A; Bernardi G; Maccarrone M; Calabresi P
    Biol Psychiatry; 2005 Jun; 57(12):1583-9. PubMed ID: 15953496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional interactions within striatal microcircuit in animal models of Huntington's disease.
    Ghiglieri V; Bagetta V; Calabresi P; Picconi B
    Neuroscience; 2012 Jun; 211():165-84. PubMed ID: 21756979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice.
    Rothe T; Deliano M; Wójtowicz AM; Dvorzhak A; Harnack D; Paul S; Vagner T; Melnick I; Stark H; Grantyn R
    Neuroscience; 2015 Dec; 311():519-38. PubMed ID: 26546830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is pharmacological neuroprotection dependent on reduced glutamate release?
    Calabresi P; Picconi B; Saulle E; Centonze D; Hainsworth AH; Bernardi G
    Stroke; 2000 Mar; 31(3):766-72; discussion 773. PubMed ID: 10700517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.
    Cummings DM; André VM; Uzgil BO; Gee SM; Fisher YE; Cepeda C; Levine MS
    J Neurosci; 2009 Aug; 29(33):10371-86. PubMed ID: 19692612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Striatal potassium channel dysfunction in Huntington's disease transgenic mice.
    Ariano MA; Cepeda C; Calvert CR; Flores-Hernández J; Hernández-Echeagaray E; Klapstein GJ; Chandler SH; Aronin N; DiFiglia M; Levine MS
    J Neurophysiol; 2005 May; 93(5):2565-74. PubMed ID: 15625098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessive-compulsive disorder.
    Wan Y; Ade KK; Caffall Z; Ilcim Ozlu M; Eroglu C; Feng G; Calakos N
    Biol Psychiatry; 2014 Apr; 75(8):623-30. PubMed ID: 23414593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease.
    Calabresi P; Centonze D; Pisani A; Bernardi G
    Exp Neurol; 1999 Jul; 158(1):97-108. PubMed ID: 10448421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
    Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
    Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium dysregulation and compensation in cortical pyramidal neurons of the R6/2 mouse model of Huntington's disease.
    Oikonomou KD; Donzis EJ; Bui MTN; Cepeda C; Levine MS
    J Neurophysiol; 2021 Oct; 126(4):1159-1171. PubMed ID: 34469694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntington's disease.
    Estrada-Sánchez AM; Castro D; Portillo-Ortiz K; Jang K; Nedjat-Haiem M; Levine MS; Cepeda C
    CNS Neurosci Ther; 2019 Apr; 25(4):509-518. PubMed ID: 30311425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.